This release removes the mention of Cleveland Clinic Weston. Partnership unites the ReBalU Protocol, Vivos's sleep platform, and a new test for cells primed for chronic disease, reaching nearly 500,000 chronic disease patients VERO BEACH, FL / ACCESS Newswire / October 29, 2026 / SOD Sciences, Inc. ("SOD Sciences" or "SOD") today announced the closing of its strategic partnership with Vivo Therapeutics, Inc. (Nasdaq:VVOS) ("Vivos"). Vivos has acquired an 11% equity interest in SOD Sciences, a 50% ownership interest in SOD's pseudohypoxia patent, and a 50% ownership interest in SOD's pseudohypoxia early‑warning test, the ReBalU Primed Cell Test, in exchange for $12,000,000 of Vivos Series D Convertible Preferred Stock, convertible at $0.15 per share into 80,000,000 shares of Vivos common stock and subject to a 4.99% beneficial ownership blocker. SOD retains ownership of its other patents and its ReBalU Protocol. The partnership at a glance A strategic investor. Vivos, a Nasdaq‑listed leader in the treatment of obstructive sleep apnea, becomes an 11% shareholder in SOD Sciences, and SOD becomes a holder of Vivos convertible preferred stock. A shared patent. SOD and Vivos each own 50% of SOD's pseudohypoxia patent. A shared test. SOD and Vivos share 50/50 in the contribution margin on every ReBalU Primed Cell Test sold, through every channel, by either company. ReBalU for Vivos customers. SOD and Vivos market the ReBalU Protocol to Vivos's customers on a 50/50 basis. A national market. The ReBalU Primed Cell Test is marketed nationwide, to the more than 2,600sleep centers in the United States and to chronic‑disease practices. Nearly 500,000 patients. SOD's channels with a large South Florida Hospital Chain, American Health Associates (AHA),and Vivos target nearly 500,000 patients with chronic disease. The ReBalU Protocol The ReBalU Protocol, SOD's lead product family, is built on SOD's founding principle: almost all chronic diseases stem from an imbalance in the body's antioxidant system. That imbalance begins with genetic insufficiencies in key antioxidant alleles. Life insults then drive key biomarkers in the wrong direction until the reduced glutathione reserve falls below the individual's critical point, and chronic disease follows. Chronic disease accounts for 90% of the nation's $5.3 trillion in annual health care spending. The ReBalU Protocol works in three steps: Test. A CLIA laboratory test measures the individual's antioxidant genotype and reduced glutathione reserve. Treat. A patent‑pending, GRAS‑based combination of the ReBalU gummie and a swallowable mouthwash raises the body's own endogenous butyrate and DHA to rebuild the reserve. Retest. The individual is tested again to confirm that the reserve has improved. The ReBalU Protocol is a medical food. SOD is about to begin an Institutional Review Board study of the ReBalU Test/Treat/Retest Protocol at a large South Florida Hospital Chain, which SOD believes will demonstrate the protocol's ability to improve the reduced glutathione reserve through increased endogenous butyrate together with DHA. Why sleep is the starting point Sleep‑disturbance diseases are the earliest physical warning signs of chronic disease. That is why the partnership with Vivos places both companies at the forefront of personalized medicine. Each individual is tested against their own baseline, treated, and retested to see whether their reduced glutathione reserve has improved and their disease is retreating. What pseudohypoxia is Pseudohypoxia is a state in which a cell behaves as if it is starved of oxygen even when oxygen is present. The cell switches on its hypoxia survival program, led by the protein HIF‑1α, and shifts its metabolism away from mitochondrial respiration toward glycolysis, the same shift seen in chronic disease and cancer. In obstructive sleep apnea, the driver is the repeated cycle of oxygen desaturation and reoxygenation that occurs every night. Intermittent hypoxia raises HIF‑1α and switches on its target genes, including those for glycolysis, and each reoxygenation sends a burst of oxidative and nitrosative stress through the cell that drains its glutathione reserve. What the medical community knows today Pseudohypoxia is well established in the research literature. Diabetes researchers described "hyperglycemic pseudohypoxia" as a driver of diabetic complications in 1993. Harvard researchers identified a pseudohypoxic state as a cause of mitochondrial decline in aging in 2013. Cancer biologists recognize HIF‑1α activation under normal oxygen as a core feature of tumor metabolism. Sleep medicine is moving the same way. The field has long graded sleep apnea by counting breathing events, but NIH‑funded research has shown that the "hypoxic burden" of nightly desaturation explains much of the cardiovascular risk of sleep apnea. Yet physicians have had no routine clinical test that tells a patient their cells are in a pseudohypoxic state. The science is matur